Shares of Edap Tms SA (NASDAQ:EDAP) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $6.50 for the company and are expecting that the company will post ($0.03) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Edap Tms an industry rank of 122 out of 255 based on the ratings given to its competitors.
Several equities analysts recently commented on EDAP shares. ValuEngine raised Edap Tms from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. TheStreet raised Edap Tms from a “d+” rating to a “c” rating in a research report on Tuesday, June 26th. HC Wainwright reissued a “buy” rating and set a $6.50 price target on shares of Edap Tms in a research report on Monday, July 2nd. Finally, Zacks Investment Research lowered Edap Tms from a “hold” rating to a “sell” rating in a research report on Friday, September 7th.
Shares of NASDAQ:EDAP opened at $2.91 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.45 and a quick ratio of 2.04. Edap Tms has a 1 year low of $2.07 and a 1 year high of $4.25. The stock has a market cap of $82.64 million, a PE ratio of -291.00 and a beta of 0.53.
Edap Tms (NASDAQ:EDAP) last released its quarterly earnings results on Wednesday, August 29th. The medical equipment provider reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $10.14 million for the quarter, compared to analyst estimates of $10.74 million. Edap Tms had a negative return on equity of 4.04% and a negative net margin of 3.55%. sell-side analysts forecast that Edap Tms will post -0.03 EPS for the current year.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Further Reading: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.